Pavel A. Petukhov

Pavel A. Petukhov

Auto-generated profile, based on publicly available information

Pavel A. Petukhov

Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois, Chicago, IL 60612, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2011 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RNRaghupathi Neelarapu
Raghupathi Neelarapu
DHDenise L. Holzle
Denise L. Holzle
SVSubash Velaparthi
Subash Velaparthi
HBHe Bai
He Bai
MBMichael Brunsteiner
Michael Brunsteiner
PPPavel A. Petukhov
Pavel A. Petukhov

3 November 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BHBai He
Bai He
SVSubash Velaparthi
Subash Velaparthi
GPGilles Pieffet
Gilles Pieffet
CPChris Pennington
Chris Pennington
AMAruna Mahesh
Aruna Mahesh
PPPavel A. Petukhov
Pavel A. Petukhov

22 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
VPValentina Z. Petukhova
Valentina Z. Petukhova
SASammy Yaw Aboagye
Sammy Yaw Aboagye
Matteo ArdiniMatteo Ardini
Matteo Ardini
RLRachel P. Lullo
Rachel P. Lullo
FFFrancesca Fata
Francesca Fata
PPPavel A. Petukhov
Pavel A. Petukhov
Only praziquantel is available for treating schistosomiasis, a disease affecting more than 200 million people. Praziquantel-resistant worms have been selected for in the lab and low cure rates from mass drug administration programs suggest that resistance is evolving in the field. Thioredoxin glutathione reductase (TGR) is essential for schistosome survival and a validated drug target. TGR inhibitors identified to date are irreversible and/or covalent inhibitors with unacceptable off-target effects. In this work, we identify noncovalent TGR inhibitors with efficacy against schistosome infections in mice, meeting the criteria for lead progression indicated by WHO. Comparisons with previous in vivo studies with praziquantel suggests that these inhibitors outperform the drug of choice for schistosomiasis against juvenile worms.

1 August 2017 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
TTTaha Y Taha
Taha Y Taha
SAShaimaa M. Aboukhatwa
Shaimaa M. Aboukhatwa
RKRachel C. Knopp
Rachel C. Knopp
NINaohiko Ikegaki
Naohiko Ikegaki
HAHazem Abdelkarim
Hazem Abdelkarim
PPPavel A. Petukhov
Pavel A. Petukhov

25 May 2018 in ACS Chemical Biology
Verified
Journal Article
Closed access
ISIlaria Silvestri
Ilaria Silvestri
HLHaining Lyu
Haining Lyu
FFFrancesca Fata
Francesca Fata
GBGiovanna Boumis
Giovanna Boumis
Adriana Erica MieleAdriana Erica Miele
Adriana Erica Miele
FAFrancesco Angelucci
Francesco Angelucci

15 January 2020 in ACS Infectious Diseases
Verified
Journal Article
Closed access
HLHaining Lyu
Haining Lyu
PPPavel A. Petukhov
Pavel A. Petukhov
PBPaul R. Banta
Paul R. Banta
AJAjit Jadhav
Ajit Jadhav
WLWendy A. Lea
Wendy A. Lea
DWDavid L. Williams
David L. Williams